{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:08:57Z","timestamp":1789675737952,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"DOI":"10.1007\/s00270-025-04262-w","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:52:06Z","timestamp":1762354326000},"page":"514-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Outcomes and Prognostic Factors After Yttrium-90 Resin-Based Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: A Single-Center Experience"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9344-5938","authenticated-orcid":false,"given":"Lorenzo","family":"Braccischi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Federico","family":"Garducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Taninokuchi Tomassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Della Gala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Strigari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arber","family":"Golemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lodi Rizzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"De Cinque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Modestino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mosconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"4262_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261\u201380. https:\/\/doi.org\/10.1038\/nrgastro.2016.51.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4262_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Kl\u00fcmpen H-J, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry. J Hepatol. 2022;76:1109\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.010.","journal-title":"J Hepatol"},{"issue":"S1","key":"4262_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(S1):19\u201331. https:\/\/doi.org\/10.1111\/liv.14095.","journal-title":"Liver Int"},{"key":"4262_CR4","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol. 2022;77:1690\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.022.","journal-title":"J Hepatol"},{"key":"4262_CR5","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.21037\/tcr-23-1278","volume":"12","author":"J-Q Yang","year":"2023","unstructured":"Yang J-Q, Wang X-G, Wu B. Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database. Transl Cancer Res. 2023;12:3007\u201315. https:\/\/doi.org\/10.21037\/tcr-23-1278.","journal-title":"Transl Cancer Res"},{"key":"4262_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","volume":"79","author":"D Alvaro","year":"2023","unstructured":"Alvaro D, Gores GJ, Walicki J, Hassan C, Sapisochin G, Komuta M, et al. EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79:181\u2013208. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.010.","journal-title":"J Hepatol"},{"key":"4262_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid"},{"key":"4262_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"D-Y Oh","year":"2024","unstructured":"Oh D-Y, He AR, Bouattour M, Okusaka T, Qin S, Chen L-T, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694\u2013704. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4262_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A, Deneau M, Forman L, Ilyas SI, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77:659\u2013702. https:\/\/doi.org\/10.1002\/hep.32771.","journal-title":"Hepatology"},{"key":"4262_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"key":"4262_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/hbsn.2016.11.02","volume":"6","author":"LJ Savic","year":"2017","unstructured":"Savic LJ, Chapiro J, Geschwind J-FH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. Hepatobiliary Surg Nutr. 2017;6:7\u201321. https:\/\/doi.org\/10.21037\/hbsn.2016.11.02.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"4262_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/COC.0b013e3181f47583","volume":"35","author":"A Kennedy","year":"2012","unstructured":"Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Radioembolization for the treatment of liver tumors: general principles. Am J Clin Oncol. 2012;35:91\u20139. https:\/\/doi.org\/10.1097\/COC.0b013e3181f47583.","journal-title":"Am J Clin Oncol"},{"key":"4262_CR13","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s00270-024-03768-z","volume":"47","author":"G Keane","year":"2024","unstructured":"Keane G, Lam M, Braat A, Bruijnen R, Kaufmann N, De Jong H, et al. Transarterial radioembolization (TARE) global practice patterns: an international survey by the Cardiovascular and Interventional Radiology Society of Europe (CIRSE). Cardiovasc Intervent Radiol. 2024;47:1224\u201336. https:\/\/doi.org\/10.1007\/s00270-024-03768-z.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4262_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6:51. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3702.","journal-title":"JAMA Oncol"},{"key":"4262_CR15","doi-asserted-by":"publisher","first-page":"1270264","DOI":"10.3389\/fgstr.2023.1270264","volume":"2","author":"MA Cocozza","year":"2023","unstructured":"Cocozza MA, Braccischi L, De Cinque A, Bruno A, Cappelli A, Renzulli M, et al. Unresectable intrahepatic cholangiocarcinoma: TARE or TACE, which one to choose? Front Gastroenterol. 2023;2:1270264. https:\/\/doi.org\/10.3389\/fgstr.2023.1270264.","journal-title":"Front Gastroenterol"},{"key":"4262_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/bjc.2016.191","volume":"115","author":"C Mosconi","year":"2016","unstructured":"Mosconi C, Gramenzi A, Ascanio S, Cappelli A, Renzulli M, Pettinato C, et al. Yttrium-90 radioembolization for unresectable\/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer. 2016;115:297\u2013302. https:\/\/doi.org\/10.1038\/bjc.2016.191.","journal-title":"Br J Cancer"},{"key":"4262_CR17","doi-asserted-by":"publisher","first-page":"153303382311556","DOI":"10.1177\/15330338231155690","volume":"22","author":"C Mosconi","year":"2023","unstructured":"Mosconi C, Cacioppa LM, Cappelli A, Gramenzi AG, Vara G, Modestino F, et al. Update of the bologna experience in radioembolization of intrahepatic cholangiocarcinoma. Technol Cancer Res Treat. 2023;22:153303382311556. https:\/\/doi.org\/10.1177\/15330338231155690.","journal-title":"Technol Cancer Res Treat"},{"key":"4262_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"4262_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-025-04200-w","author":"D Filippiadis","year":"2025","unstructured":"Filippiadis D, Pereira PL, Hausegger KA, Ryan AG, Binkert CA. CIRSE standards of practice for the classification of complications: the modified CIRSE classification system. Cardiovasc Intervent Radiol. 2025. https:\/\/doi.org\/10.1007\/s00270-025-04200-w.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4262_CR20","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682\u201399. https:\/\/doi.org\/10.1007\/s00259-021-05600-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4262_CR21","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00270-024-03825-7","volume":"47","author":"MA Cocozza","year":"2024","unstructured":"Cocozza MA, Dajti E, Braccischi L, Modestino F, Reimer P, Cucchetti A, et al. Survival after transarterial radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: an updated meta-analysis and meta-regression. Cardiovasc Intervent Radiol. 2024;47:1313\u201324. https:\/\/doi.org\/10.1007\/s00270-024-03825-7.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4262_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102258","volume":"99","author":"J Edeline","year":"2021","unstructured":"Edeline J, Lamarca A, McNamara MG, Jacobs T, Hubner RA, Palmer D, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. Cancer Treat Rev. 2021;99:102258. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102258.","journal-title":"Cancer Treat Rev"},{"key":"4262_CR23","doi-asserted-by":"publisher","unstructured":"Rees CA, Pica N, Monuteaux MC, Bourgeois FT. Noncompletion and nonpublication of trials studying rare diseases: a cross-sectional analysis. In: Kruk ME, editor. PLOS Med. 2019. 16:e1002966. https:\/\/doi.org\/10.1371\/journal.pmed.1002966","DOI":"10.1371\/journal.pmed.1002966"},{"key":"4262_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1159\/000525489","volume":"11","author":"SL Chan","year":"2022","unstructured":"Chan SL, Chotipanich C, Choo SP, Kwang SW, Mo F, Worakitsitisatorn A, et al. Selective internal radiation therapy with Yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma: a phase 2 single-arm multicenter clinical trial. Liver Cancer. 2022;11:451\u20139. https:\/\/doi.org\/10.1159\/000525489.","journal-title":"Liver Cancer"},{"key":"4262_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/HEP.0000000000000544","volume":"79","author":"J Edeline","year":"2024","unstructured":"Edeline J, Bridgewater J, Campillo-Gimenez B, Neveu E, Phelip J-M, Neuzillet C, et al. Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: data from clinical trials. Hepatology. 2024;79:96\u2013106. https:\/\/doi.org\/10.1097\/HEP.0000000000000544.","journal-title":"Hepatology"},{"key":"4262_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101279","volume":"7","author":"N Adamus","year":"2025","unstructured":"Adamus N, Edeline J, Henriques J, Fares N, Lecomte T, Turpin A, et al. First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: the French ACABi GERCOR PRONOBIL cohort. JHEP Rep. 2025;7:101279. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101279.","journal-title":"JHEP Rep"},{"key":"4262_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00270-023-03657-x","volume":"47","author":"P Reimer","year":"2024","unstructured":"Reimer P, Vilgrain V, Arnold D, Balli T, Golfieri R, Loffroy R, et al. Factors impacting survival after transarterial radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: a combined analysis of the prospective CIRT studies. Cardiovasc Intervent Radiol. 2024;47:310\u201324. https:\/\/doi.org\/10.1007\/s00270-023-03657-x.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4262_CR28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00270-022-03183-2","volume":"45","author":"AN Gupta","year":"2022","unstructured":"Gupta AN, Gordon AC, Gabr A, Kalyan A, Kircher SM, Mahalingam D, et al. Yttrium-90 radioembolization of unresectable intrahepatic cholangiocarcinoma: long-term follow-up for a 136-patient cohort. Cardiovasc Intervent Radiol. 2022;45:1117\u201328. https:\/\/doi.org\/10.1007\/s00270-022-03183-2.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4262_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1245\/s10434-022-12708-5","volume":"30","author":"J Edeline","year":"2023","unstructured":"Edeline J, Rolland Y, Campillo-Gimenez B, Bourien H, Trochet M, Garin E, et al. Selective internal radiation therapy (Yttrium-90 glass microspheres) combined with capecitabine in the neoadjuvant setting of operable intrahepatic CHOlangiocarcinoma: the SIROCHO trial design. Ann Surg Oncol. 2023;30:21\u20132. https:\/\/doi.org\/10.1245\/s10434-022-12708-5.","journal-title":"Ann Surg Oncol"},{"key":"4262_CR30","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.21037\/jgo-23-210","volume":"14","author":"S Young","year":"2023","unstructured":"Young S, Torkian P, Flanagan S, D\u2019Souza D, Sanghvi T, Golzarian J. Intrahepatic cholangiocarcinoma: a dose threshold evaluation in those undergoing transarterial radioembolization. J Gastrointest Oncol. 2023;14:2202\u201311. https:\/\/doi.org\/10.21037\/jgo-23-210.","journal-title":"J Gastrointest Oncol"},{"key":"4262_CR31","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1007\/s00270-021-02834-0","volume":"44","author":"B Cheng","year":"2021","unstructured":"Cheng B, Villalobos A, Sethi I, Wagstaff W, Galt J, Brandon D, et al. Determination of tumor dose response thresholds in patients with chemorefractory intrahepatic cholangiocarcinoma treated with resin and glass-based Y90 radioembolization. Cardiovasc Intervent Radiol. 2021;44:1194\u2013203. https:\/\/doi.org\/10.1007\/s00270-021-02834-0.","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04262-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-025-04262-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04262-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:38:59Z","timestamp":1772721539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-025-04262-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4262"],"URL":"https:\/\/doi.org\/10.1007\/s00270-025-04262-w","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was not supported by any funding. The authors declare that they have no conflict of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. Consent for publication was obtained for every individual person\u2019s data included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"conflict of interest"}}]}}